Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospectively Randomized Phase III Trial, Studying the Benefits of Adjuvant Sequential vs. Combined Taxane Based Chemotherapy, Followed by Different Biological Treatment Strategies in Early, HER2-positive Breast Cancer

Trial Profile

Prospectively Randomized Phase III Trial, Studying the Benefits of Adjuvant Sequential vs. Combined Taxane Based Chemotherapy, Followed by Different Biological Treatment Strategies in Early, HER2-positive Breast Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2015

At a glance

  • Drugs Docetaxel (Primary) ; Gemcitabine (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil; Goserelin; Letrozole; Tamoxifen
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Acronyms SUCCESS-B
  • Most Recent Events

    • 06 Jun 2012 New source identified and integrated (German Clinical Trials Register, DRKS00003641).
    • 02 Apr 2012 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
    • 02 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top